Expert Interview
NOT EXECUTED/OBSOLETE - What Should We Look for in Auris' August Phase 3 Data for Acute Inner Ear Tinnitus Drug AM-101
Ticker(s): EARSAn ENT specialist with experience dealing with acute inner ear tinnitus.
This project was proposed to the Slingshot community to get an expert's opinion in anticipation of the data release, but did not receive enough interest to be executed.
The data was released on 8.18.16 and as such this project will not be executed. Note: At time of posting stock was down 60% highlighting the importance of this catalyst.
What is your experience with acute inner ear tinnitus?
Added By: kcmckeeHow effective are current treatments (like tinnitus retraining and psychological drugs) in your opinion?
Added By: kcmckeeWhat are your thoughts on the TACTT2 data thus far? What would you expect to see in Phase 3?
Added By: kcmckeeAuras says high stress on the ears can lead to extra-cellular glutamate, which in turn cause excessive activation of cochlear NMDA receptors. There drug aims to block the NMDA receptors. Does this science seem like something that would work?
Added By: kcmckeeHow do you treat acute inner tinnitus right now? Why? Would you consider using something like AM-101?
Added By: kcmckeeAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
- Completed Enrollment of TACTT2 and TACTT3 Phase 3 studies of AM-101 for Acute Inner Ear Tinnitis Expected by mid-2016 EARS Occurred On: Mar 30, 2016
- First top-line Phase 3 clinical data for AM-101 in acute inner ear tinnitus EARS Occurred On: Aug 18, 2016
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
